Simultaneous vertical guided bone regeneration and guided tissue regeneration in the posterior maxilla using recombinant human platelet-derived growth factor: a case report.

Loma Linda University, Loma Linda, Calif, USA.
Journal of Oral Implantology (Impact Factor: 0.98). 01/2009; 35(5):251-6. DOI: 10.1563/AAID-JOI-D-09-00004.1
Source: PubMed

ABSTRACT This clinical case report describes and demonstrates successful use of recombinant human platelet-derived growth factor (rhPDGF-BB) in conjunction with autogenous bone, anorganic bone mineral, and barrier membranes to reconstruct severe alveolar bone defects. A combined sinus augmentation and vertical alveolar ridge augmentation was successfully performed. In addition, a significant amount of periodontal bone gain was achieved in close apposition to a previously denuded root surface, which is significant from a periodontal standpoint, given the possibility of vertical periodontal regeneration.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Provide a comprehensive overview on the clinical use and the efficacy of growth factors in different reconstructive procedures in the oral maxillofacial area. A systematic review of the literature on the clinical use of human and human recombinant growth factors in oral maxillofacial reconstruction has been performed. The use of autogenous growth factors in platelet concentrates (PCs) has shown to be beneficial in the treatment of intrabony pockets at a reasonable level of evidence by improving probing depth and clinical attachment levels as well as linear bone fill within the limits of the observation periods. The application in conjunction with non-autogenous graft materials has been superior to the use of PCs only or grafting materials alone. No benefits have been shown for the use of PCs in recession treatment. When used in furcation treatment, probing depth, clinical attachment level and linear bone fill have been reported to improve significantly, however, without clinical benefit. No benefit for the final outcome could be shown for the use of PCs neither in sinus lift procedures nor in lateral / vertical crest augmentations. The use of human recombinant growth factors has been so far limited almost exclusively to rhPDGF-BB and rhBMPs (BMP-2, BMP-7 and GDF-5). The use of rhPDGF in the treatment of intrabony pockets has shown a reliable increase in linear bone fill but weaker evidence for permanent improvements of clinical attachment level. So far there is no evidence to support the use in recession treatment, sinus lift procedures and socket healing as well as lateral / vertical augmentations of the alveolar crest. rhBMPs have shown to be effective in enhancing bone formation in socket healing (rhBMP-2) and sinus lift procedures (rhBMP-2 and GDF-5). No controlled studies are available for the use in mandibular segmental repair. Successful reports on this application appear to be limited to primary reconstruction after ablative surgery for benign pathology with preservation of the periosteum. Evidence of clinical efficacy of growth factors in reconstructive procedures in the oral and maxillofacial area is limited.
    Clinical Implant Dentistry and Related Research 07/2013; · 3.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Platelet-derived growth factor-BB (PDGF-BB) plays important roles in regenerating damaged tissue. In this study we investigated the effects of a tissue-engineered bone combined with recombinant human PDGF-BB (rhPDGF-BB), bone marrow stem cells (BMSCs) and β-tricalcium phosphate (β-TCP) to repair critical-size calvarial bone defects in rat. Proliferation and osteogenic differentiation of BMSCs treated with different concentration rhPDGF-BB (0, 10, and 50 ng/ml) was evaluated by MTT, alkaline phosphatase (ALP) activity, alizarin red staining and real-time quantitative PCR (RT-qPCR) analysis of osteogenic gene. BMSCs were then combined with rhPDGF-BB-loaded β-TCP and transplanted into 5 mm calvarial bone defects. The new bone formation and mineralization was evaluated by micro-computerized tomography (Micro-CT) and histological analysis at week 8 after operation. It was observed that the proliferation of BMSCs treated with rhPDGF-BB was enhanced with a time- and dose- dependent manner. There were increased ALP activity, mineralized deposition and elevated mRNA levels of osteogenic gene for BMSCs treated with rhPDGF-BB, particularly in the 50 ng/ml group. Histological analysis showed new bone formation and mineralization in the rhPDGF-BB/BMSCs/β-TCP group was significantly higher than BMSCs/β-TCP, rhPDGF-BB/β-TCP, and β-TCP alone group (P < 0.05). In conclusion, rhPDGF-BB/BMSCs/β-TCP is a promising tissue-engineered bone for craniofacial bone regeneration.
    Journal of Materials Science Materials in Medicine 02/2012; 23(4):1073-84. · 2.14 Impact Factor
  • Source
    Implant Dentistry - The Most Promising Discipline of Dentistry, 09/2011; , ISBN: 978-953-307-481-8


Available from
Aug 15, 2014